Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Glutamic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM8 | O00222 | 2/20 | 0.50 |
| ▸ | GRM6 | O15303 | 2/20 | 0.50 |
| ▸ | GRM7 | Q14831 | 2/20 | 0.50 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.50 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.50 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.50 |
| ▸ | GSR | P00390 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.50 |
| ▸ | GRM5 | P41594 | 1/20 | 0.50 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.50 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.50 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.50 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.50 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.50 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.50 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.50 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.50 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.50 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| D-Glutamate SCHEMBL27622200 | 1.00 | GRM8 (0.50) | GRM8GRM6GRM7GRM4GRIN2D | |
| Glutamic Acid SCHEMBL16290410 | 0.96 | GRM8 (0.55) | GRM8GRM6GRM7GRM4GRIN2D | |
| D-Glutamate SCHEMBL27218911 | 0.96 | GRM8 (0.55) | GRM8GRM6GRM7GRM4GRIN2D | |
| D-Glutamate SCHEMBL2201557 | 0.96 | GRM8 (0.55) | GRM8GRM6GRM7GRM4GRIN2D | |
| Glutamic Acid SCHEMBL515160 | 0.96 | GRM8 (0.55) | GRM8GRM6GRM7GRM4GRIN2D | |
| D-Glutamate SCHEMBL27572769 | 0.96 | GRM8 (0.55) | GRM8GRM6GRM7GRM4GRIN2D | |
| D-Glutamate SCHEMBL28774544 | 0.93 | GSR (0.48) | GRM8GRM6GRM7GRM4GRIN2D | |
| Glutamic Acid SCHEMBL8584930 | 0.93 | GRIK1 (0.43) | GRM8GRM6GRM7GRM4GRIN2D | |
| Glutamic Acid SCHEMBL7748011 | 0.93 | GRIK1 (0.43) | GRM8GRM6GRM7GRM4GRIN2D | |
| Lysine SCHEMBL7616708 | 0.93 | GSR (0.48) | GRM8GRM6GRM7GRM4GRIN2D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 172 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023242844-A1 | METHOD AND THERAPEUTIC AGENT FOR TREATMENT OF DISEASE OR DISORDER ASSOCIATED WITH IMPAIRED FIRING RATE AND/OR MITOCHONDRIAL CALCIUM HOMEOSTASIS | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2023-12-21 | — | — | WO | claimed |
| CN-112142855-A | Protein for diabetes treatment, protein conjugate and application thereof | 爱德迪安（北京）生物技术有限公司 | 2020-12-29 | — | — | CN | claimed |
| US-20190142963-A1 | FGF21 C-TERMINAL PEPTIDE OPTIMIZATION | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION | 2019-05-16 | — | — | US | claimed |
| US-10233225-B2 | Single chain insulin agonists exhibiting high activity at the insulin receptor | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2019-03-19 | — | — | US | claimed |
| US-10232020-B2 | Incretin-insulin conjugates | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2019-03-19 | — | — | US | claimed |
| US-20190076553-A1 | METHODS AND ASSAYS FOR TREATING SUBJECTS WITH SHANK3 DELETION, MUTATION OR REDUCED EXPRESSION | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2019-03-14 | — | — | US | claimed |
| EP-3442997-A2 | FGF21 C-TERMINAL PEPTIDE OPTIMIZATION | Indiana University Research & Technology Corporation (US) | 2019-02-20 | — | — | EP | claimed |
| CN-109180802-A | Compound, composition with hypoglycemic effect and application thereof | 爱德迪安（北京）生物技术有限公司 | 2019-01-11 | — | — | CN | claimed |
| EP-2793932-B1 | CTP-BASED INSULIN ANALOGS FOR TREATMENT OF DIABETES | UNIV INDIANA RES & TECH CORP (US) | 2018-10-03 | — | — | EP | claimed |
| CN-108271356-A | INCRETIN-INSULIN CONJUGATES | 印第安纳大学研究及科技有限公司 | 2018-07-10 | — | — | CN | claimed |
| US-20140178307-A1 | METHODS AND ASSAYS FOR TREATING SUBJECTS WITH SHANK3 DELETION, MUTATION OR REDUCED EXPRESSION | MOUNT SINAI SCHOOL OF MEDICINE (US) | 2014-06-26 | — | — | US | claimed |
| EP-2582719-A2 | SINGLE CHAIN INSULIN AGONISTS EXHIBITING HIGH ACTIVITY AT THE INSULIN RECEPTOR | Indiana University Research And Technology Corporation (US) | 2013-04-24 | — | — | EP | claimed |
| EP-2571515-A2 | METHODS AND ASSAYS FOR TREATING SUBJECTS WITH SHANK3 DELETION, MUTATION OR REDUCED EXPRESSION | Mount Sinai School of Medicine (US) | 2013-03-27 | — | — | EP | claimed |
| US-20120216302-A1 | METHODS AND ASSAYS FOR TREATING SUBJECTS WITH SHANK3 DELETION, MUTATION OR REDUCED EXPRESSION | MOUNT SINAI SCHOOL OF MEDICINE (US) | 2012-08-23 | — | — | US | claimed |
| WO-2011159882-A2 | NOVEL STABILIZED INSULIN AGONISTS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2011-12-22 | — | — | WO | claimed |
| WO-2011159895-A2 | SINGLE CHAIN INSULIN AGONISTS EXHIBITING HIGH ACTIVITY AT THE INSULIN RECEPTOR | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2011-12-22 | — | — | WO | claimed |
| WO-2011146109-A2 | METHODS AND ASSAYS FOR TREATING SUBJECTS WITH SHANK3 DELETION, MUTATION OR REDUCED EXPRESSION | MOUNT SINAI SCHOOL OF MEDICINE (US) | 2011-11-24 | — | — | WO | claimed |
| EP-2376099-A1 | YL-BASED INSULIN-LIKE GROWTH FACTORS EXHIBITING HIGH ACTIVITY AT THE INSULIN RECEPTOR | Indiana University Research & Technology Corporation (US) | 2011-10-19 | — | — | EP | claimed |
| US-20110245164-A1 | YL-BASED INSULIN-LIKE GROWTH FACTORS EXHIBITING HIGH ACTIVITY AT THE INSULIN RECEPTOR | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2011-10-06 | — | — | US | claimed |
| WO-2010080607-A1 | YL-BASED INSULIN-LIKE GROWTH FACTORS EXHIBITING HIGH ACTIVITY AT THE INSULIN RECEPTOR | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2010-07-15 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190142963-A1 | FGF21 C-TERMINAL PEPTIDE OPTIMIZATION | FGF23, FGFR1, FGFR3 | GRM8 2372/4885GRM6 2626/4885GRM7 2448/4885 |
| US-10233225-B2 | Single chain insulin agonists exhibiting high activity at the insulin receptor | IGF1R, GPR119, IRS1 | GRM8 462/4885GRM6 473/4885GRM7 741/4885 |
| US-10232020-B2 | Incretin-insulin conjugates | GPR119, GLP1R, GIPR | GRM8 684/4885GRM6 358/4885GRM7 297/4885 |
| US-20110245164-A1 | YL-BASED INSULIN-LIKE GROWTH FACTORS EXHIBITING HIGH ACTIVITY AT THE INSULIN RECEPTOR | IGF1R, INSR, IGFBP1 | GRM8 1739/4885GRM6 2311/4885GRM7 691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.